In Reply

Letters to the Editor regarding the article Onconephrology: The Significance of Renal Function for the Development, Diagnosis, and Treatment Of Cancer by Susanne Delecluse, Fridtjof Harder, Frieder Keller, Martin Zeier, and Stefanie Zschäbitz in issue 24/2024

In their discussion of our article (1), Fromm et al. explain an important adverse effect of tumor medications—a certainly important observation that is worth considering, especially in the context of obviously lacking clarification in the relevant prescribing information. Determining renal function by means of creatinine-independent measuring methods in this and other situations is certainly recommended (2).

DOI: 10.3238/arztebl.m2025.0022

On behalf of the authors

PD Dr. med. Susanne Delecluse

Universitätsklinikum Heidelberg

Fachklinik für Nierenerkrankungen

Nierenzentrum

Conflict of interest statement

The author declares that no conflict of interest exists.

References

1. Delecluse S, Harder F, Keller F, Zeier M, Zschäbitz S: Onconephrology: The significance of renal function for the development, diagnosis, and treatment of cancer. Dtsch Arztebl Int 2024; 121: 793–9

2. Kitchlu A, Silva V, Anand S, et al.: Assessment of GFR in patients with cancer: A statement from the American Society of Onco-Nephrology. Clin J Am Soc Nephrol 2024; 19: 1061–72